Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 13

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 13
---
 depend on multiple factors. As a result, our management will have broad discretion in 
 the application of the net proceeds of this offering. For additional information regarding the repayment of the Bridge Loan, see   
 “Certain Relationships and Related Party Transactions – Other Financings.”                                                         |

<div align='center'>11</div>

| Risk                    
 factors                 |     | Investing in                                                                                                             
 our securities involves a high degree of risk. You should read the “Risk Factors” starting on page 15 of this prospectus 
 for a discussion of factors to consider carefully before deciding to invest in our Ordinary Shares.                      |
| NYSE                    
 American trading symbol |     | Our Ordinary Shares have                                                                                                 
 been approved for listing on the NYSE American under the symbol “RGNT”.                                                  |

The number of the Ordinary Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as of the date of this prospectus. This number excludes:

| ● | 79,290 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to consultants under our incentive option plan outstanding as of such date, at an exercise 
 price of $3.97, of which 79,290 were vested as of such date;                                                                     |

| ● | 465,533 Ordinary Shares issuable                                                                        
 upon the exercise of options to be issued to the Chairman of our board of directors upon the completion 
 of this offering under our incentive option plan, at an exercise price of NIS 0.004;                    |

| ● | 191,473 Ordinary Shares                                                                                                            
 issuable upon the exercise of options to be issued to consultants and certain investors upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | 140,000 Ordinary Shares                                  
 underlying warrants issuable to the Bridge Loan lenders; |

| ● | 61,539 Ordinary Shares                                            
 underlying warrants issuable to the 2024 Loan Agreements lenders; |

| ● | 55,224 Ordinary Shares                                                     
 underlying warrants issuable to the Company’s chief executive officer; and |

| ● | 92,309 Ordinary Shares underlying warrants issuable to lenders under the 2025 Loan 
 Agreements.                                                                        |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to:

| ● | no exercise of the Representative’s’ 
 over-allot